Reply. Kastritis E. et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone containing regimes and the impact of novel agents. Haematologica 2007; 92:546-9.
Bergner
R
R
Medizinische Klinik A, Klinikum der Stadt Ludwigshafen GmbH, Bremserstrasse 79, 67063 Ludwigshafen, Germany. bergnerr@klilu.de
Hoffmann
M
M
Uppenkamp
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001536:Bence Jones Protein / Q000652:urine; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D003907:Dexamethasone / Q000008:administration & dosage*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009194:Myeloma Proteins / Q000032:analysis; D011507:Proteinuria / Q000209:etiology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009194:Myeloma Proteins; D003907:Dexamethasone; D001536:Bence Jones Protein; D003404:Creatinine